Cargando…
A decade comparison of regulatory decision patterns for oncology products to all other non‐oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration
Consensus of regulatory decisions on the same Marketing Authorization Application (MAA) are critical for stakeholders. In this context, regulatory decision patterns from the Swissmedic (SMC), the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA) were analyzed for hemato‐...
Autores principales: | Rohr, Ulrich‐P., Iovino, Mario, Rudofsky, Leonie, Li, Qiyu, Juritz, Stephanie, Gircys, Arunas, Wildner, Oliver, Bujar, Magda, Bolte, Claus, Dalla Torre di Sanguinetto, Simon, Wolfer, Anita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499418/ https://www.ncbi.nlm.nih.gov/pubmed/37408165 http://dx.doi.org/10.1111/cts.13567 |
Ejemplares similares
-
Collaborative training of regulators as an approach for strengthening regulatory systems in LMICs: experiences of the WHO and Swissmedic
por: Dehaghi, Razieh Ostad Ali, et al.
Publicado: (2023) -
Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice
por: Rodier, Céline, et al.
Publicado: (2020) -
Reported hepatotoxicity and hepatotoxicity guidance in the product information of protein kinase inhibitors in oncology registered at the European Medicines Agency
por: Maliepaard, Marc, et al.
Publicado: (2023) -
Cardio‐Oncology at the Beginning of a New Decade
por: Grumbach, Isabella M.
Publicado: (2020) -
Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials
por: Rondon, Aurélie, et al.
Publicado: (2021)